Kato H, Takashima T, Kishikawa H, Emura S, Ohmori K
Department of Internal Medicine, Saga Medical School, Japan.
Int J Clin Pharmacol Res. 1996;16(4-5):99-102.
Test results concerning platelet behavior in vitro, particularly aggregation, are frequently abnormal in diabetic patients. The concept has therefore arisen that platelet hyper-reactivity is one factor contributing to diabetic microangiopathy. We report here the antiplatelet effect of beraprost sodium, a chemically stable prostaglandin I2 analogue made in Japan, in 6 diabetic patients. Platelet aggregation induced by adenosine 5'-diphosphate (10 microM) after administration of beraprost sodium (40 micrograms every 8 h for 14 days) was significantly decreased as compared with levels before beraprost sodium administration. These results indicate the possibility that the occurrence of vascular complications in diabetes mellitus can be suppressed by long-term administration of beraprost sodium.
糖尿病患者体外血小板行为的检测结果，尤其是聚集功能，常常异常。因此出现了这样一种概念，即血小板高反应性是导致糖尿病微血管病变的一个因素。我们在此报告日本生产的化学稳定的前列腺素I2类似物贝拉普罗斯钠对6例糖尿病患者的抗血小板作用。在给予贝拉普罗斯钠（每8小时40微克，共14天）后，由5'-二磷酸腺苷（10微摩尔）诱导的血小板聚集与给予贝拉普罗斯钠之前的水平相比显著降低。这些结果表明，长期给予贝拉普罗斯钠有可能抑制糖尿病血管并发症的发生。
